Payment overview · 2025
General Payments
$1,540.24
91 reported records · 22 companies
Healthcare provider profile · identity verified
Philip Stitzer, DO
Allopathic & Osteopathic Physicians|Family Medicine · MOBERLY, MO · NPI 1881693323
Verified facts
What the public records show
CMS Open Payments records show Philip Stitzer, DO received $1,540.24 in general payments during 2025 across 91 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $288.61 | 18.7% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $249.07 | 16.2% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $217.40 | 14.1% | 20 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $197.06 | 12.8% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $101.75 | 6.6% | 5 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $62.59 | 4.1% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $47.69 | 3.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.72 | 2.7% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.02 | 2.5% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $37.26 | 2.4% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.67 | 2.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.34 | 2.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.55 | 2.0% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $26.57 | 1.7% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $23.90 | 1.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.44 | 1.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.78 | 1.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.67 | 1.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.98 | 1.0% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $14.53 | 0.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.93 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.71 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,540.24 | 91 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $226.47 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $188.20 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $170.52 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $170.52 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $160.01 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $145.16 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $109.27 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $103.38 | 11 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $83.71 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $77.40 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $66.22 | 8 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $62.59 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $53.78 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $52.82 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $48.93 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $47.69 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $39.02 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $37.26 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $34.67 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $26.57 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $26.54 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $23.90 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.26 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 28 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 64 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 72 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 95 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
28 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
83 | 12 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
95 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
197 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 829 | 145 |
| Atorvastatin Calcium | Atorvastatin Calcium | 808 | 168 |
| Levothyroxine Sodium | Levothyroxine Sodium | 703 | 136 |
| Gabapentin | Gabapentin | 443 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 429 | 74 |
| Lisinopril | Lisinopril | 408 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 382 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 365 | 69 |
| Clonazepam | Clonazepam | 363 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 328 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 321 | 69 |
| Alprazolam | Alprazolam | 315 | 54 |
| Metformin Hcl | Metformin Hcl | 314 | 68 |
| Potassium Chloride | Potassium Chloride | 305 | 55 |
| Glimepiride | Glimepiride | 303 | 53 |
| Losartan Potassium | Losartan Potassium | 301 | 69 |
| Prednisone | Prednisone | 301 | 152 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 277 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 275 | 58 |
| Simvastatin | Simvastatin | 267 | 55 |
| Spironolactone | Spironolactone | 265 | 47 |
| Tramadol Hcl | Tramadol Hcl | 257 | 55 |
| Montelukast Sodium | Montelukast Sodium | 254 | 48 |
| Sertraline Hcl | Sertraline Hcl | 234 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 230 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 227 | 29 |
| Allopurinol | Allopurinol | 224 | 45 |
| Pregabalin | Pregabalin | 219 | 45 |
| Trazodone Hcl | Trazodone Hcl | 207 | 35 |
| Furosemide | Furosemide | 206 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 199 | 34 |
| Meloxicam | Meloxicam | 199 | 34 |
| Torsemide | Torsemide | 199 | 39 |
| Eliquis | Apixaban | 197 | 31 |
| Lorazepam | Lorazepam | 197 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 189 | 39 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 166 | 23 |
| Famotidine | Famotidine | 161 | 26 |
| Carvedilol | Carvedilol | 152 | 33 |
| Lovastatin | Lovastatin | 151 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 30 |
| Metformin Hcl Er | Metformin Hcl | 149 | 30 |
| Doxazosin Mesylate | Doxazosin Mesylate | 146 | 26 |
| Celecoxib | Celecoxib | 145 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 23 |
| Nortriptyline Hcl | Nortriptyline Hcl | 140 | 26 |
| Irbesartan | Irbesartan | 134 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 127 | 22 |
| Mirtazapine | Mirtazapine | 125 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 116 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 38 |
| Ezetimibe | Ezetimibe | 107 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 100 | 26 |
| Bupropion Hcl Sr | Bupropion Hcl | 98 | 14 |
| Cefuroxime | Cefuroxime Axetil | 96 | 75 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 19 |
| Rybelsus | Semaglutide | 95 | 14 |
| Xarelto | Rivaroxaban | 95 | 12 |
| Azithromycin | Azithromycin | 94 | 67 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 87 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 86 | suppressed |
| Glipizide | Glipizide | 85 | 18 |
| Buspirone Hcl | Buspirone Hcl | 84 | 12 |
| Diazepam | Diazepam | 84 | 12 |
| Alendronate Sodium | Alendronate Sodium | 83 | 13 |
| Levetiracetam | Levetiracetam | 83 | 12 |
| Trulicity | Dulaglutide | 83 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 81 | 47 |
| Temazepam | Temazepam | 80 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 16 |
| Fluconazole | Fluconazole | 78 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 75 | 16 |
| Naproxen | Naproxen | 73 | 13 |
| Nystatin | Nystatin | 73 | 22 |
| Ozempic | Semaglutide | 72 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 72 | 16 |
| Acyclovir | Acyclovir | 69 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 69 | 19 |
| Minocycline Hcl | Minocycline Hcl | 67 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 66 | suppressed |
| Aripiprazole | Aripiprazole | 64 | 11 |
| Bupropion Xl | Bupropion Hcl | 64 | 15 |
| Cephalexin | Cephalexin | 64 | 45 |
| Farxiga | Dapagliflozin Propanediol | 64 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 63 | 21 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 61 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 12 |
| Atenolol | Atenolol | 58 | 14 |
| Finasteride | Finasteride | 57 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 57 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 57 | suppressed |
| Topiramate | Topiramate | 57 | suppressed |
| Baclofen | Baclofen | 56 | 12 |
| Ibuprofen | Ibuprofen | 56 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 55 | 41 |
| Imipramine Hcl | Imipramine Hcl | 55 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 15 |
| Olanzapine | Olanzapine | 53 | 13 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 52 | 12 |
| Memantine Hcl | Memantine Hcl | 51 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 50 | suppressed |
| Anastrozole | Anastrozole | 48 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 48 | suppressed |
| Synthroid | Levothyroxine Sodium | 47 | 12 |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 46 | suppressed |
| Lamotrigine | Lamotrigine | 46 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 46 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 45 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 45 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 44 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 42 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 41 | suppressed |
| Lansoprazole | Lansoprazole | 41 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 40 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 39 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 30 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 38 | suppressed |
| Amoxicillin | Amoxicillin | 37 | 30 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 36 | suppressed |
| Latanoprost | Latanoprost | 35 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Glipizide Er | Glipizide | 34 | suppressed |
| Linzess | Linaclotide | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 33 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 32 | 12 |
| Digoxin | Digoxin | 32 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 31 | 11 |
| Vascepa | Icosapent Ethyl | 31 | suppressed |
| Indapamide | Indapamide | 30 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 15 |
| Ketoconazole | Ketoconazole | 29 | 12 |
| Risperidone | Risperidone | 29 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 29 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 28 | 28 |
| Ipratropium Bromide | Ipratropium Bromide | 28 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 28 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 19 |
| Propranolol Hcl Er | Propranolol Hcl | 27 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 27 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Cartia Xt | Diltiazem Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Modafinil | Modafinil | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Sulfasalazine | Sulfasalazine | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Vraylar | Cariprazine Hcl | 23 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 12 |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 22 | suppressed |
| Methimazole | Methimazole | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 19 |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 12 |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 18 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 18 | suppressed |
| Testosterone | Testosterone | 18 | suppressed |
| Clozapine | Clozapine | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Nadolol | Nadolol | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Etodolac | Etodolac | 16 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 15 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Acetylcysteine | Acetylcysteine | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Prevalite | Cholestyramine | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | 12 |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Probenecid | Probenecid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,540.24 · 91 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, EVENITY, FANAPT, FARXIGA, JARDIANCE, JOURNAVX, LEQVIO, LINZESS, M-M-R II, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PENMENVY, PREVNAR 20, PROQUAD, QULIPTA, REPATHA, REXULTI, ROTATEQ, Rybelsus, Senza, The Cologuard Plus Collection Kit, UBRELVY, VAXELIS, VAXNEUVANCE, VOQUEZNA, VRAYLAR, Wegovy, YUPELRI, ZAVZPRET, ZENPEP, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error